NCT05032144View on ClinicalTrials.gov

The Safety and Tolerability of STSA-1002 Following Intravenous Infusion in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 28, 2021

Primary Completion Date

March 31, 2022

Study Completion Date

March 31, 2022

Conditions
Healthy
Interventions
DRUG

STSA-1002 injection

Intravenous injection

DRUG

Placebo

Intravenous injection

DRUG

STSA-1002 injection

Intravenous injection

DRUG

Placebo

Intravenous injection

DRUG

STSA-1002 injection

Intravenous injection

DRUG

Placebo

Intravenous injection

DRUG

STSA-1002 injection

Intravenous injection

DRUG

Placebo

Intravenous injection

DRUG

STSA-1002 injection

Intravenous injection

DRUG

Placebo

Intravenous injection

Trial Locations (1)

66212

AltaSciences Clinical Kansas, Inc, Overland Park

All Listed Sponsors
lead

Staidson (Beijing) Biopharmaceuticals Co., Ltd

INDUSTRY

NCT05032144 - The Safety and Tolerability of STSA-1002 Following Intravenous Infusion in Healthy Subjects | Biotech Hunter | Biotech Hunter